Toronto, Ontario–(Newsfile Corp. – November 19, 2024) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a biotech firm creating the trade’s main telomere expertise platform with diagnostic and prognostic purposes measuring genomic instability in oncology, is happy to announce that its software to the IPON program (Mental Property Ontario) was authorised. The IPON program leverages the innovation of Ontario enterprises in securing and increasing their mental property (IP) portfolio. This system gives coaching, advisory companies and monetary help. Inside the program Telo could obtain as much as CAD 80,000 of reimbursement for its potential IP prices along with strategic enter and steerage.
Telo Genomics holds an IP patent portfolio of 23 patents and pending patent purposes in Canada, US and Europe. The portfolio contains patents that govern its core 3D telomere expertise TeloView, and illness/ software particular patents together with hematological issues, prostate most cancers, Alzheimer’s illness and circulating tumor cells (liquid biopsy) expertise. Twenty out of the twenty-three patents are totally granted.
The newest patent purposes filed by Telo help mental property safety of its flagship product for smoldering a number of myeloma TeloViewSMM. The Firm filed two patent purposes in 2022 and 2023. These patents at the moment are within the worldwide section (PCT) having been filed in Canada, the US and Europe. These 2 innovations present safety for Telo’s strategies to stratify smoldering myeloma sufferers into their respective threat group, a serious unmet medical want. When granted these patents would defend Telo’s expertise into 2043.
Telo’s flagship prognostic take a look at TeloViewSMM for smoldering a number of myeloma (SMM) sufferers was clinically validated in collaboration with the Mayo Clinic and Dana Farber Institute of Most cancers. The take a look at is now accessible as a CLIA laboratory developed take a look at (LDT). SMM sufferers are generally not handled till they progress to full stage a number of myeloma (MM), a lethal incurable blood most cancers. TeloViewSMM with the perfect reported sensitivity for the evaluation of this illness, stratifies SMM right into a high-risk group that may profit from instant therapy intervention to delay and doubtlessly keep away from development to full stage MM. Additional, the take a look at additionally confirms the steadiness of the SMM illness in low-risk sufferers. These sufferers will be monitored over time utilizing the TeloViewSMM take a look at with out exposing these sufferers to pointless invasive pattern collections and debilitating chemotherapy therapies. Critically, TeloViewSMM can be utilized periodically as a non-invasive liquid biopsy take a look at that may be carried out utilizing a easy blood draw. Current demographic research have proven that SMM prevalence gives a big market alternative with an estimated 0.5% of the inhabitants over 40 years previous being affected, which suggests that the whole TeloViewSMM addressable market might lead to over 500,000 exams per 12 months.
“We are thrilled to join the IPON program. The program is highly competitive and only select technology developers with a strong and meaningful innovation footprint are considered,” mentioned Sherif Louis, Telo’s President and CTO. “Telo holds a robust patent portfolio that protects all the IP aspects of our business. We are continuously reviewing our IP strategy and technology development to expand this portfolio. We were indeed forward thinking with our recent smoldering myeloma filings that provide protection for our TeloViewSMM test until 2043.”
About TELO
Telo Genomics Corp. is a biotech firm pioneering probably the most complete telomere platform within the trade with highly effective purposes and prognostic options. These embody liquid biopsies and associated applied sciences in oncology and neurological ailments. Liquid biopsy is a quickly rising area of great curiosity to the medical group for being much less invasive and extra simply replicated than conventional diagnostic approaches. By combining our crew’s appreciable experience in quantitative evaluation of 3D telomeres with molecular biology and synthetic intelligence to acknowledge illness related genetic instability, Telo is creating easy and correct merchandise that enhance day-to-day take care of sufferers by serving the wants of pathologists, clinicians, tutorial researchers and drug builders. The advantages of our proprietary expertise have been substantiated in 160+ peer reviewed publications and in 30+ medical research involving greater than 3,000 sufferers with a number of cancers and Alzheimer’s illness. Our lead software, TELO-MM is being developed to supply necessary, actionable data to medical professionals within the therapy of a number of myeloma, a lethal type of blood most cancers. For extra data, please go to www.telodx.com.
Neither the TSX Enterprise Trade nor its Regulation Providers Supplier (as such time period is outlined within the insurance policies of the TSX Enterprise Trade) accepts duty for the adequacy or accuracy of this launch.
Cautionary Notice Concerning Ahead-Trying Statements
Sure data contained herein could represent “forward-looking information” below Canadian securities laws. Typically, forward-looking data will be recognized by means of forward-looking terminology akin to “intends”, “will”, or variations of such phrases and phrases or statements that sure actions, occasions or outcomes “will” happen. Ahead-looking statements concerning the medical efficacy of merchandise, business viability of merchandise, use of proceeds, and the flexibility of the TeloView® platform to ship personalised drugs leading to higher therapies and outcomes are based mostly on the Firm’s estimates and are topic to recognized and unknown dangers, uncertainties and different components which will trigger the precise outcomes, degree of exercise, efficiency or achievements of the Firm to be materially completely different from these expressed or implied by such forward-looking statements or forward-looking data, together with capital expenditures and different prices. There will be no assurance that such statements will show to be correct, as precise outcomes and future occasions might differ materially from these anticipated in such statements. Accordingly, readers shouldn’t place undue reliance on forward- wanting statements and forward-looking data. The Firm won’t replace any forward-looking statements or forward-looking data which might be integrated by reference herein, besides as required by relevant securities legal guidelines.
To view the supply model of this press launch, please go to https://www.newsfilecorp.com/launch/230533
